Danirixin, another selective CXCR2 antagonist with high affinity, is able to effectively inhibit the binding of CXCL8 (IL‐8) to CXCR2, and several clinical trials have focused on its improvement of lung function in patients with mild to severe COPD (NCT03136380, NCT03250689, NCT03034967, and NCT02130193). Here, CXCR2 is linked to chronic obstructive pulmonary disease.